Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 21,427	$ 26,585
Short-term investments	198,013	135,734
Prepaid expenses and other current assets	6,955	3,628
Total current assets	226,395	165,947
Property and equipment, net	206	270
In-process R&D	11,111	10,960
Other non-current assets	1,105	387
Total assets	238,817	177,564
Current liabilities:
Accounts payable	4,609	3,504
Accrued expenses and other current liabilities	8,179	7,093
Total current liabilities	12,788	10,597
Long-term liabilities:
Long-term debt	26,552	26,348
Other long-term liabilities	128	247
Total liabilities	39,468	37,192
Commitments and Contingencies (Note 9)
Stockholders’ equity:
Common stock, $0.001 par value, 300,000,000 authorized as of September 30, 2024 and December 31, 2023; 170,842,763 and 138,143,545 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	172	140
Additional paid-in capital	659,084	533,872
Accumulated other comprehensive income (loss)	299	(271)
Accumulated deficit	(460,206)	(393,369)
Total stockholders’ equity	199,349	140,372
Total liabilities and stockholders’ equity	$ 238,817	$ 177,564

In-process research and development.

No definition available.

Name:	svra_InProcessResearchAndDevelopment
Namespace Prefix:	svra_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).